Silverback Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation immunotherapies designed to selectively activate and engage the body’s innate and adaptive immune responses against cancer and other diseases. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary Cite™ platform to engineer targeted innate immune activators that homing in on tumor-associated antigens, thereby minimizing systemic toxicity and enhancing anti-tumor efficacy. Since its founding in 2020, Silverback has rapidly advanced multiple programs into clinical and preclinical stages, underscoring its commitment to addressing significant unmet needs in oncology and beyond.
At the core of Silverback’s pipeline are its tumor-directed innate immune activators. SBT6050, a HER2-targeted TLR8 agonist, is being evaluated in solid tumors driven by HER2 overexpression, while SBT6290, a CD20-targeted TLR8 agonist, is designed for B-cell malignancies. In parallel, Silverback is developing cytokine-based immune cell engagers, including programs targeting interleukin-12 (IL-12) and interleukin-2 (IL-2) superagonists fused to tumor-binding domains. These modular molecules are engineered to concentrate cytokine activity within the tumor microenvironment, with the goal of enhancing T-cell expansion and function without the dose-limiting toxicities associated with systemic cytokine administration.
Silverback also maintains research collaborations in areas such as neurodevelopmental disorders, exemplified by its early-stage SB-121 program for autism spectrum disorder. The company’s leadership team, led by CEO Zachari Thomas, combines deep expertise in immuno-oncology, protein engineering and clinical development. Supported by a board of directors and scientific advisors with extensive drug discovery and commercialization experience, Silverback Therapeutics is positioned to translate its novel immunotherapy platforms into new treatment options for patients worldwide.
AI Generated. May Contain Errors.
Free SBTX Stock Alerts